12.31 USD
▼-0.21-0.81%
2026-08-03
市值
$140.67M
市盈率
—
EPS
-6.82
股息率
—
52 周区间
4.86 – 17.40
成交量
152.21K
Beta
2.15
目标价
27.50
52W 低 4.8652W 高 17.40
价格走势
公司简介
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain met...